Standard Health Record FHIR Implementation Guide

SHR BrcaReceptorStatusVS ValueSet

SHR BrcaReceptorStatusVS ValueSet

Classification of receptor status in breast cancer.

Defining URL:http://standardhealthrecord.org/shr/oncology/vs/BrcaReceptorStatusVS
Name:SHR BrcaReceptorStatusVS ValueSet
Definition:

Classification of receptor status in breast cancer.

Publisher:The MITRE Corporation: Standard Health Record Collaborative
Source ResourceXML / JSON / Turtle
Downloads: XML, JSON, Turtle

Expansion

This value set contains 4 concepts

Expansion based on http://standardhealthrecord.org/shr/oncology/cs/BrcaReceptorStatusCS version 0.0.1

All codes from system http://standardhealthrecord.org/shr/oncology/cs/BrcaReceptorStatusCS

CodeDisplayDefinition
luminal_AGroup 1. Includes tumors that are ER positive and PR positive, but negative for HER2. Luminal A breast cancers are likely to benefit from hormone therapy and may also benefit from chemotherapy.Group 1. Includes tumors that are ER positive and PR positive, but negative for HER2. Luminal A breast cancers are likely to benefit from hormone therapy and may also benefit from chemotherapy.
luminal_BGroup 2. Includes tumors that are ER positive, PR negative and HER2 positive. Luminal B breast cancers are likely to benefit from chemotherapy and may benefit from hormone therapy and treatment targeted to HER2.Group 2. Includes tumors that are ER positive, PR negative and HER2 positive. Luminal B breast cancers are likely to benefit from chemotherapy and may benefit from hormone therapy and treatment targeted to HER2.
HER2_positiveGroup 3. Includes tumors that are ER negative and PR negative, but HER2 positive. HER2 breast cancers are likely to benefit from chemotherapy and treatment targeted to HER2.Group 3. Includes tumors that are ER negative and PR negative, but HER2 positive. HER2 breast cancers are likely to benefit from chemotherapy and treatment targeted to HER2.
Triple_negativeGroup 4. Also called basal-like breast cancer, includes tumors that are ER negative, PR negative and HER2 negative. Basal-like breast cancers are likely to benefit from chemotherapy.Group 4. Also called basal-like breast cancer, includes tumors that are ER negative, PR negative and HER2 negative. Basal-like breast cancers are likely to benefit from chemotherapy.

References

This value set is used by the following profiles and extensions: